2023
Effects of Spironolactone on Arrhythmias in Hemodialysis Patients: Secondary Results of the SPin-D Randomized Controlled Trial
Mc Causland F, Hsu J, Himmelfarb J, Ikizler T, Raj D, Mehrotra R, Waikar S, Kimmel P, Kliger A, Dember L, Charytan D, Kliger A, Charytan D, Mc Causland F, Robinson E, Waikar S, Williams M, Weiner D, Aurien-Blajeni E, Cinelli M, Nizam T, Rim S, Seok P, Smith C, Curtis J, Raj D, Regunathan-Shenk R, Sharma S, Ramezani A, Andrews S, Dumadag M, Franco C, Wing M, Himmelfarb J, Mehrotra R, Anderson L, Linke L, Manahan L, Ikizler T, Hung A, Cavanaugh K, Booker C, Brannon B, Clagett A, Ellis C, Dember L, Landis J, Anderson A, Hsu J, Cifelli D, Ballard S, Durborow M, Howard T, Kuzla N, Nessel L, Tierney A, Skali H, Solomon S, Rad A, Di Carli M, Gaber M, Foster C, Kimmel P, Kusek J. Effects of Spironolactone on Arrhythmias in Hemodialysis Patients: Secondary Results of the SPin-D Randomized Controlled Trial. Kidney360 2023, 4: e486-e495. PMID: 36763641, PMCID: PMC10278797, DOI: 10.34067/kid.0000000000000067.Peer-Reviewed Original ResearchConceptsEffect of spironolactoneFrequency of bradycardiaMaintenance hemodialysisFollow-upPost hoc analysisConduction blockArrhythmic eventsCardiovascular eventsMaintenance HDSudden deathHoc analysisIncidence of cardiovascular eventsAssociation of spironolactoneDose of spironolactoneRisk of cardiovascular eventsDouble-blind trialProportion of patientsPatients treated with maintenance HDRandomized controlled trialsGeneralized estimating equation modelsSpironolactone groupPlacebo-controlledSpironolactone treatmentBradycardic eventsAge of participants
2020
Combination Hydralazine and Isosorbide Dinitrate in Dialysis-Dependent ESRD (HIDE): A Randomized, Placebo-Controlled, Pilot Trial.
Charytan D, Hsu J, Mc Causland F, Waikar S, Ikizler T, Raj D, Landis J, Mehrotra R, Williams M, DiCarli M, Skali H, Kimmel P, Kliger A, Dember L, Himmelfarb J, Anderson A, Hung A, Sharma S, Weiner D. Combination Hydralazine and Isosorbide Dinitrate in Dialysis-Dependent ESRD (HIDE): A Randomized, Placebo-Controlled, Pilot Trial. Kidney360 2020, 1: 1380-1389. PMID: 35372900, PMCID: PMC8815530, DOI: 10.34067/kid.0004342020.Peer-Reviewed Original ResearchConceptsIsosorbide dinitrateCoronary flow reserveAdverse eventsMaintenance HDMitral annular e' velocityDouble-blind pilot trialFlow reserveRecurrent intradialytic hypotensionRandomized to placeboMaximum tolerated doseTissue Doppler echocardiographyParticipants discontinued therapyGastrointestinal side effectsDetect between-group differencesPilot trialIntra-dialytic hypotensionPlacebo-ControlledPositron emission tomographyDose escalationHeart failure mortalityDose reductionStudy medicationTolerated dosePlacebo groupCombination therapy